Clinical trial
A Phase II Trial of Bolus Fluorouracil and Oxaliplatin (mFLOX) as First-line Regimen for Patients With Unresectable or Metastatic Pancreatic Cancer Not Eligible for Infusional Fluorouracil, Irinotecan and Oxaliplatin
NCT02896803 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Bolus Fluorouracil and Oxaliplatin (mFLOX) as First-line Regimen for Patients With Unresectable or Metastatic Pancreatic Cancer Not Eligible for Infusional Fluorouracil, Irinotecan and Oxaliplatin
- Lead sponsor
- Instituto do Cancer do Estado de São Paulo
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2016
- Completion date
- December 31, 2021
- Enrollment
- 37 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.